Clinical Trial Update: Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated bevacizumab plus ixabepilone in patients with advanced renal cell carcinoma; the study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Ixempra (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-06-27